Since the US Supreme Court granted cert in Oil States Energy Services, a case which challenges the constitutionality of the IPR process, the patent community has been debating whether this might mark the end of post-issuance reviews. If that were to happen, what might it mean for the patent market? According to this guest blog from Zachary Silbersher of Kroub Silbersher & Kolmykov the impact for most sectors might be more muted than anticipated, while for branded pharmaceutical companies it could be very bad news indeed. Here’s what he has to say:   

Want to read more?

Register to access two of our subscriber-only articles per month

Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts

Already registered? Log in

What our customers are saying

One of the advantages of IAM is that it is high quality and yet still accessible and relevant to the non-specialist chief executives and senior managers who don't know what they don't know about IP. It's an important contribution to the upward IP education of senior managers.

Ian Harvey
Board member
International Intellectual Property Strategists Association (INTIPSA)


Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.

Why subscribe?